Efficacy, Safety, Satisfaction, Adherence to Treatment With Nano-Formulated Cysteamine Tranexamic Acid Cream to Treat Melasma
Key Findings
An innovative cream combining cysteamine and tranexamic acid (TXA) showed significant improvement in treating subjects with epidermal melasma.
Results
Continuous improvement in melasma was observed, with modified Melasma Area and Severity Index (mMASI) scores improving by 40%, 57%, and 63% at 30, 60, and 90 days, respectively. 91% of participants experienced melasma improvement.
Conclusion
Nano-formulated cysteamine and TXA combination cream demonstrated significant efficacy in decreasing mMASI score while maintaining a strong safety profile and high patient satisfaction.
Practical Solutions and Value
Clinical trials are essential for safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research, making it easier for clinicians to access valuable knowledge. Additionally, our mobile apps support scheduling, monitoring treatments, and telemedicine, streamlining operations and improving patient care.